CYP2D6 in the metabolism of opioids for mild to moderate pain

Pharmacology

Volumn 87, Issue 5-6, 2011, Pages 274-285

  Leppert, Wojciech ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Analgesics; Cancer pain; CYP2D6; Opioids; Pain treatment; Weak opioids

Indexed keywords

CODEINE; CYTOCHROME P450 2D6; DIHYDROCODEINE; DIHYDROMORPHINE; DIPYRONE; FLUOXETINE; MACROLIDE; METOCLOPRAMIDE; MORPHINE; NALOXONE; OPIATE; PAROXETINE; PINDOLOL; PLACEBO; SERTRALINE; TRAMADOL; VORICONAZOLE;

AREA UNDER THE CURVE; CANCER PAIN; CHRONIC PAIN; CLINICAL PRACTICE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG RELEASE; ENZYME POLYMORPHISM; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; NEUROPATHIC PAIN; NONHUMAN; PAIN; PHENOTYPE; POSTOPERATIVE PAIN; PRIORITY JOURNAL; REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANALGESICS, OPIOID; ANIMALS; CYTOCHROME P-450 CYP2D6; HUMANS; NEOPLASMS; PAIN; PAIN MEASUREMENT;

EID: 79953890859     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000326085     Document Type: Review

References (77)

1. Tucker G: Advances in understanding drug metabolism and its contribution to variability in patients' response. Ther Drug Monitor 2000; 22:110-113. (Pubitemid 30083109)
2. Touw DJ: Clinical implications of genetic polymorphisms and drug interactions mediated by cytochrome P-450 enzymes. Drug Metabol Drug Interact 1997; 14:55-82. (Pubitemid 28044310)
3. Wolf CR, Smith G: Cytochrome P450 CYP2D6. IARC Sci Publ 1999; 148:209-229.
4. Ingelman-Sundberg M: Genetic polymorphism of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenom J 2005; 5: 6-13. (Pubitemid 40220611)
5. Davis MP, Homsi J: The importance of cytochrome P450 monooxygenase CYP2D6 in palliative medicine. Support Care Cancer 2001; 9: 442-451. (Pubitemid 32843631)
6. Kroemer HK, Eichelbaum M: 'It's the genes, stupid'. Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymor phism. Life Sci 1995; 56: 2285-2298.
7. Stamer UM, Stüber F: Genetic factors in pain and its treatment. Curr Opin Anaesthesiol 2007; 20: 478-484. (Pubitemid 47415138)
8. Kostka-Trabka E, Woron J: Izoenzymy cytochromu P450 a problem interakcji lekow (Polish); in Kostka-Trabka E, Woron J (eds): Interakcje Lekoww Praktyce Klinicznej. Warszawa, Wydawnictwo Lekarskie PZWL, 2006, pp 13-24.
9. Daly AK, Brochmöller J, Broly F, et al: Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996; 6: 193-201.
10. Sachse C, Brochmöller J, Bauer S, Roots I: Cytochrome P450 2D6 Variants in a Caucasian population: allele frequencies and phenotyping consequences. Am J Hum Genet 1997; 60:284-295. (Pubitemid 27058401)
11. Ingelman-Sundberg M, Oscarson M, McLellan RA: Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci 1999; 20:342-349. (Pubitemid 29366813)
12. Raimundo S, Toscano C, Klein K, et al: A novelint ronicmutation, 2988G1A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects. Clin Pharmacol Ther 2004; 76:128-138. (Pubitemid 39013403)
13. Masimirembwa CM, Hasler JA: Genetic polymorphism of drug metabolizing enzymes in African populations: implications for the use of neuroleptics and antidepressants. Brain Res Bull 1997; 44: 561-571. (Pubitemid 27494673)
14. Kirchheiner J, Keulen J-T HA, Bauer S, Roots I, Brockmöller J: Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol. J Clin Psychopharmacol 2008; 28:78-83.
15. Wang G, Zhang H, He F, Fang X: Effect of the CYP2D6*10 C188T polymorphism on postoperative tramadol analgesia in a Chinese population. Eur J Clin Pharmacol 2006; 62: 927-931. (Pubitemid 44657626)
16. Gan SH, Ismail R, Wan Adnan WA, Wan Z: Correlation of tramadol pharmacokinetics and CY P2D6*10 genotype in Malaysian subjects. J Pharm Biomed Anal 2002; 30: 189-195. (Pubitemid 35013483)
17. Hennies MH, Friderichs E, Schneider J: Receptor binding, analgesic and antitussive potency of tramadol and other selected opioids. Arzneimittelforschung 1988; 38:877-880.
18. Raffa RB, Friderichs E, Reimann W, Shank RP, Codd EE, Vaught JL: Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic. J Pharmacol Exp Ther 1992; 260: 275-285.
19. Raffa RB, Friderichs E, Reimann W, et al: Complementary and synergistic antinociceptive interaction between the enantiomers of tramadol. J Pharmacol Exp Ther 1993; 267: 331-340. (Pubitemid 23325025)
20. Dickman A: Tramadol: a review of this atypical opioid. Eur J Palliat Care 2007; 14: 181-185.
21. Lintz W, Erlaçin S, Francus E, Uragg H: Biotransformation of tramadol in man and animal. Arznneimittelforschung 1981; 31: 1932-1943. (Pubitemid 12228508)
22. Wu WN, McKown LA, Liao S: Metabolism of the analgesic drug ULTRAM® (tramadol hydrochloride) in humans: API-MS and MS/MS characterization of metabolites. Xenobiotica 2002; 32:411-425. (Pubitemid 34620945)
23. Halling J, Weihe P, Brosen K: CYP2D6 Polymorphism in relation to tramadol metabolism: a study of Faroese patients. Ther Drug Monit 2008; 30: 271-275.
24. Subrahmanyam V, Renwick AB, Walters DG, et al: Identification of cytochrome P-450 isoforms responsible for cis-tramadol metabolism in human liver microsomes. Drug Metabol Disp 2001; 29:1146-1155. (Pubitemid 32660534)
25. Gillen G, Haurand M, Kobelt DJ, Wnendt S: Affinity, potency and efficacy of tramadol and its metabolites at the cloned human μ-opioid receptor. Naunyn-Schmiedeberg's Arch Pharmacol 2000; 362:116-121. (Pubitemid 30640039)
26. Valle M, Garrido MJ, Pavón JM, Calvo R, Trocóniz IF: Pharmacokinetic-pharmacodynamic modelling of the antinociceptive effects of main active metabolites of tramadol, (+)-O-desmethyltramadol and (-)-O-desmethyltramadol, in rats. J Pharmacol Exp Ther 2000; 293:646-653. (Pubitemid 30244119)
27. Paar WD, Frankus P, Deugler HJ: The metabolism of tramadol by human liver microsomes. Clin Invest 1992; 70:708-710.
28. Klotz U, Fischer-Bosch M: Tramadol - the impact of its pharmacokinetic and pharmacodynamic properties on the clinical management of pain. Arzneimittelforschung 2003; 53: 681-687. (Pubitemid 37357353)
29. Mikus G, Somogyi AA, Bochner F, Chen ZR: Polymorphic metabolism of opioid narcotic drugs: possible clinical implications. Ann Acad Med Singapore 1991; 20: 9-12.
30. Stamer UM, Lehnen K, Höthker F, Bayerer B, Wolf S, Hoeft A, Stuber F: Impact of CYP2D6 genotype on postoperative tramadol analgesia. Pain 2003; 105:231-238. (Pubitemid 37162492)
31. Stamer U, Musshoff F, Kobilay M, Madea B, Hoeft A, Stuber F: Concentrations of tramadol and O-desmethyltramadol enantiomers in different CY2D6 genotypes. Clin Pharmacol Ther 2007; 82: 41-47. (Pubitemid 46944194)
32. Stamer U, Stuber F, Muders T, Musshoff F: Respiratory depression with tramadol in a patient with renal impairment and CYP2D6 gene duplication. Anesth Analg 2008; 107: 926-929.
33. Garrido MJ, Sayar O, Segura C, et al: Pharmacokinetic/pharmacodynamic modelling of the antinociceptive effects of (+)-tramadol in the rat: role of cytochrome P450 2D activity. J Pharmacol Exp Ther 2003; 305: 710-718. (Pubitemid 36459191)
34. Paar WD, Poche S, Gerloff J, Dengler HJ: Polymorphic CYP2D6 mediates O-demethylation of the opioid analgesic tramadol. Eur J Clin Pharmacol 1997; 53: 235-239. (Pubitemid 28018297)
35. Egberts ACG, Borgh JT, Brodie-Meijer CCE: Serotonin syndrome attributed to tramadol addition to paroxetine therapy. Int Clin Psychopharmacol 1997; 12: 181-182. (Pubitemid 27283328)
36. Mason BJ, Blackburn KH: Possible serotonin syndrome associated with tramadol and sertraline administration. Ann Pharmacother 1997; 31:175-177. (Pubitemid 27074104)
37. Sauget D, Franco PS, Amaniou M, Mazere J, Dantoine T: Possible syndrome sérotoninergique induit par l'association de tramadol à de la sertraline chez une femme âgée. Thérapie 2002; 57: 309-310. (Pubitemid 35190866)
38. Davies MP: Tramadol; In Davies MP, Glare P, Hardy J (eds): Opioids in Cancer Pain. Oxford, Oxford University Press, 2005, pp 69-82.
39. 3 spinal receptor involvement in acute pain in humans. Anesth Analg 2002; 94: 1533-1577.
40. Grond S, Sablotzki A: Clinical pharmacology of tramadol. Clin Pharmacokinet 2004; 43:879-923. (Pubitemid 39447033)
41. Gasse CBS, Derby L, Vasilakis-Scaramozza C, Jick H: Incidence of first-time idiopathic seizures in users of tramadol. Pharmacotherapy 2000; 20: 629-634. (Pubitemid 30387678)
42. Rojas-Corrales MO, Ortega-Alvaro A, Gibert-Rahola J, Roca-Vinardell A, Micó JA: Pindolol, a β-adrenoceptor blocker/5-hydroxytryptamine1A/1B antagonist, enhances the analgesic effect of tramadol. Pain 2000; 88:119-124.
43. Sindrup SH, Madsen C, Brøsen K, Jensen TS: The effect of tramadol in painful polyneuropathy in relation to serum drug and metabolite levels. Clin Pharmacol Ther 1999; 66: 636-641. (Pubitemid 30014092)
44. Poulsen L, Arendt-Nielsen L, Brøsen K, Sindrup SH: The hypoalgesic effect of tramadol in relation to CYP2D6. Clin Pharmacol Ther 1996; 60:636-644. (Pubitemid 27025910)
45. Teppema LJ, Nieuwenhuijs D, Olievier CN, Dahan A: Respiratory depression by tramadol in the cat. Anesthesiology 2003; 98:420-427.
46. Barnung SK, Treschow M, Borgbjerg FM: Respiratory depression following oral tramadol in a patient with impaired renal function. Pain 1997; 71: 111-112. (Pubitemid 27245238)
47. Mikus G, Weiss J: Influence of CYP2D6 genetics on opioid kinetics, metabolism and response. Curr Pharmacogenom 2005; 3:43-52. (Pubitemid 40352698)
48. Leppert W: Tramadol as an analgesic for mild to moderate cancer pain. Pharmacol Rep 2009; 61:978-992.
49. Leppert W, Luczak J: The role of tramadol in cancer pain treatment - a review. Support Care Cancer 2005; 13: 5-17. (Pubitemid 40193060)
50. Gravenstein JS, Smith GM, Sphire RD, Isaacs JP, Beecher HK: Dihydrocodeine. N Engl J Med 1956; 254: 877-885.
51. Keats AS, Telford J, Kurosu Y: Studies of analgesic drugs: dihydrocodeine. J Pharmacol Exp Ther 1957; 120: 354-360.
52. Robertson JR: Dihydrocodeine: second strand of treatment for drug misusers. Drug Alcohol Rev 1996; 15:200-201.
53. Ammon S, Hofmann U, Griese EU, Gugeler N, Mikus G: Pharmacokinetics of dihydrocodeine and its active metabolite after single and multiple oral dosing. Br J Clin Pharmacol 1999; 48:317-322. (Pubitemid 29417713)
54. Rowell FJ, Seymour RA, Rawlins MD: Pharmacokinetics of intravenous and oral dihydrocodeine and its acid metabolites. Eur J Clin Pharmacol 1983; 25:419-424. (Pubitemid 13005592)
55. Frazer NM, Galloway DB, Lockwood GF, McKeller J, Quinn KG: Single- and multiple-dose pharmacokinetic studies of DHC Continus tablets 60 mg, a novel dihydrocodeine preparation; in Doyle D (ed): 1986 Int Symp Pain Control. R Soc Med Serv Int Congr Symp Ser, No 123. London, Royal Society of Medicine Services, 1987, pp 101-107.
56. Schmidt H, Vormfelde SV, Walchner-Bonjean M, et al: The role of active metabolites in dihydrocodeine effects. Int J Clin Pharmacol Ther 2003; 41:95-106. (Pubitemid 36348269)
57. Fromm MF, Hofmann U, Griese EU, Mikus G: Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans. Clin Pharmacol Ther 1995; 58: 374-382.
58. Schmidt H, Vormfelde SV, Klinder K, et al: Affinities of dihydrocodeine and its metabolites to opioid receptors. Pharmacol Toxicol 2002; 91:57-63.
59. Webb JA, Rostami-Hodjegan A, Abdul-Manap R, Hofmann U, Mikus G, Kamali F: Contribution of dihydrocodeine and dihydromorphine to analgesia following dihydrocodeine administration in man: a PK-PD modelling analysis. Br J Clin Pharmacol 2001; 52: 35-43. (Pubitemid 32862767)
60. Jurna I, Kömen W, Baldauf J, Fleischer W: Analgesia by dihydrocodeine is not due to formation of dihydromorphine: evidence from nociceptive activity in rat thalamus. J Pharmacol Exp Ther 1997; 281: 1164-1170. (Pubitemid 27258373)
61. Wilder-Smith CH, Hufschmid E, Thormann W: The visceral and somatic antinociceptive effects of dihydrocodeine and its metabolite, dihydromorphine. A cross-over study with extensive and quinidine-induced poor metabolizers. Br J Clin Pharmacol 1998; 45: 575-581. (Pubitemid 28270913)
62. Kirkwood LC, Nation RL, Somogyi AA: Characterization of the human cytochrome P450 enzyme involved in the metabolism of dihydrocodeine. Br J Clin Pharmacol 1997; 44: 549-555. (Pubitemid 27517481)
63. Kirkwood LC, Nation RL, Somogyi AA: Glucuronidation of dihydrocodeine by human liver microsomes and the effect of inhibitors. Clin Exp Pharmacol Physiol 1998; 25: 266-270. (Pubitemid 28162294)
64. Armstrong SC, Cozza KL: Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, part II. Psychosomatics 2003; 44: 515-520. (Pubitemid 37352231)
65. Moore RA, Collins L, Carroll D, McQuay H: Paracetamol with and without codeine in acute pain: a quantitative systematic review. Pain 1997; 70: 193-201. (Pubitemid 27179631)
66. Lötsch J, Skarke C, Schmidt H, Rohrbacher M, Hofmann U, Schwab M, Geisslinger G: Evidence for morphine-independent central nervous opioid effects after administration of codeine: contribution of other codeine metabolites. Clin Pharmacol Ther 2006; 79: 35-48. (Pubitemid 43069577)
67. Vree TB, van Dongen RTM, Koopman-Kimenai PM: Codeine analgesia is due to codeine-6-glucuronide, not morphine. Int J Clin Pract 2000; 54: 395-398. (Pubitemid 30604052)
68. Vree TB, Verwey-van Wissen CP: Pharmacokinetics and metabolism of codeine in humans. Biopharm Drug Disp 1992; 13: 445-460.
69. Gasche Y, Daali Y, Fathi M, et al: Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med 2004; 351: 2827-2831. (Pubitemid 40051906)
70. Kirchheiner J, Schmidt H, Tzetkov M, Keulen JT, Lötsch J, Roots I, Brockmöller J: Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J 2007; 7:257-265. (Pubitemid 47202488)
71. Eckhardt K, Li S, Ammon S, Schänzle G, Mikus G, Eichelbaum M: Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. Pain 1998; 76:27-33. (Pubitemid 28304939)
72. Sindrup SH, Brøsen K, Bjerring P, et al: Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine. Clin Pharmacol Ther 1991; 49:686-693.
73. Sindrup SH, Hofmann U, Asmussen J, et al: Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake. Eur J Clin Pharmacol 1996; 49: 503-509. (Pubitemid 26094574)
74. Poulsen L, Brøsen K, Arendt-Nielsen L, Gram LF, Elbæk K, Sindrup SH: Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. Eur J Clin Pharmacol 1996; 51: 289-295. (Pubitemid 26422976)
75. Yue QY, Svensson JO, Alm C, Sjöqvist F, Säwe J: Interindividual and interethnic difference in the methylation and glucuronidation of codeine. Br J Clin Pharmacol 1989; 28: 629-637. (Pubitemid 20003948)
76. Caraco Y, Sheller J, Wodd AJJ: Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects. J Pharmacol Exp Ther 1999; 290:413-422. (Pubitemid 29302351)
77. Thompson CM, Wojno H, Greiner E, May EL, Rice KC, Selley DE: Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at μ- and 8-opioid receptors. J Pharmacol Exp Ther 2004; 308: 547-554. (Pubitemid 38134216)